# **Data Changes for the CCDD MAR Release Candidate 2021**

## **Based on the QA Release** 20210301

|  |  |
| --- | --- |
| Data entered by | Barbara Prime |
| Data checked by | Jo-Anne Hutsul |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
|  | [NONE] |

## **NTP File**

### **Deprecation**

The following NTP concept(s) need to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
| 9002743 | bacillus Calmette-Guérin substrain TICE 800000000 unit per vial powder for solution for injection | bacille de Calmette-Guérin sous-souche TICE 800000000 unité par fiole poudre pour solution injectable | Deprec |
| 9001076 | ciprofloxacin (ciprofloxacin, ciprofloxacin hydrochloride) 1000 mg prolonged-release oral tablet | ciprofloxacine (ciprofloxacine, chlorhydrate de ciprofloxacine) 1000 mg comprimé oral à libération prolongée | Deprec |
| 9001049 | ciprofloxacin (ciprofloxacin, ciprofloxacin hydrochloride) 500 mg prolonged-release oral tablet | ciprofloxacine (ciprofloxacine, chlorhydrate de ciprofloxacine) 500 mg comprimé oral à libération prolongée | Deprec |
| 9014414 | tozinameran 30 mcg per 0.3 mL suspension for injection 1.5 mL vial | tozinaméran 30 mcg par 0,3 mL suspension injectable 1,5 mL fiole | Deprec |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
| 9014432 | mRNA-1273 SARS-CoV-2 100 mcg per 0.5 mL dispersion for injection 5 mL vial | da63c2674396eade2865bada2ff7ebe0 |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9013880 | gramicidin 0.025 mg per mL and polymyxin B (polymyxin B sulfate) 10000 unit per mL ophthalmic drops |
| 9013882 | gramicidin 0.025 mg per mL and polymyxin B (polymyxin B sulfate) 10000 unit per mL otic drops |

## **MP File**

### **Deprecation (very rare)**

**No new deprecated concepts**

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For both DINs, they have had additional UoP added. Both products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
| 02182971 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 1000 mg par 40 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |
| 02182777 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 500 mg par 20 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |

The following MP concepts are generating as active but need to be set to **deprecated**. For both products, they have been assigned a new DIN (02474891, 02474735). This will have to be done manually each month.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
| 77700322 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |
| 77700323 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Whitelist to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 11028 | 830267 | DOCUSATE SODIUM CAP 100MG USP (docusate sodium 100 mg oral capsule) LABORATOIRES TRIANON INC. | Cancelled Postmarket Exp. 2021.02.28 |
| 42841 | 2182742 | FLUOROURACIL INJECTION USP (fluorouracil 50 mg per mL solution for injection 100 mL vial) PFIZER CANADA ULC | Cancelled Postmarket Exp. 2021.02.28 |
| 80107 | 2315548 | ARTHRITIS EXTRA STRENGTH ROLL-ON LOTION (capsaicin 0.035 % and menthol 1.25 % and trolamine salicylate 10 % lotion) CHURCH & DWIGHT CANADA CORP | Cancelled Postmarket Exp. 2021.02.28 |
| 81288 | 2327562 | ACT OLANZAPINE ODT (olanzapine 5 mg orodispersible tablet) TEVA CANADA LIMITED | Cancelled Postmarket Exp. 2020.04.30 |
| 81289 | 2327570 | ACT OLANZAPINE ODT (olanzapine 10 mg orodispersible tablet) TEVA CANADA LIMITED | Cancelled Postmarket Exp. 2020.05.31 |
| 81290 | 2327589 | ACT OLANZAPINE ODT (olanzapine 15 mg orodispersible tablet) TEVA CANADA LIMITED | Cancelled Postmarket Exp. 2020.05.31 |
| 81291 | 2327597 | ACT OLANZAPINE ODT (olanzapine 20 mg orodispersible tablet) TEVA CANADA LIMITED | Cancelled Postmarket Exp. 2020.05.31 |
| 88073 | 2395657 | FENTANYL PATCH (fentanyl 12 mcg per hour transdermal patch) PRO DOC LIMITEE | Cancelled Postmarket Exp. 2021.02.28 |
| 89348 | 2408740 | DESLORATADINE ALLERGY CONTROL (desloratadine 5 mg oral tablet) DOMINION PHARMACAL | Cancelled Postmarket Exp. 2021.02.28 |
| 89825 | 2413604 | CARBAMAZEPINE CR (carbamazepine 400 mg prolonged-release oral tablet) PRO DOC LIMITEE | Cancelled Postmarket Exp. 2021.02.28 |
| 94456 | 2457512 | ANTIBIOTIC DROPS (gramicidin 0.025 mg per mL and polymyxin B (polymyxin B sulfate) 10000 unit per mL ophthalmic/otic drops) SANDOZ CANADA INCORPORATED | Dormant 2019.03.01 |
| 94586 | 2458705 | ANTIBIOTIC EAR DROPS (gramicidin 0.025 mg per mL and polymyxin B (polymyxin B sulfate) 10000 unit per mL otic drops) SANDOZ CANADA INCORPORATED | Dormant 2020.08.29 |
| 94587 | 2458713 | ANTIBIOTIC EYE DROPS (gramicidin 0.025 mg per mL and polymyxin B (polymyxin B sulfate) 10000 unit per mL ophthalmic drops) SANDOZ CANADA INCORPORATED | Dormant 2020.11.28 |
| 96746 | 2476614 | APO-HYDROMORPHONE CR (hydromorphone hydrochloride 3 mg prolonged-release oral capsule) APOTEX INC | Dormant 2020.02.08 |
| 96747 | 2476622 | APO-HYDROMORPHONE CR (hydromorphone hydrochloride 4.5 mg prolonged-release oral capsule) APOTEX INC | Dormant 2020.01.29 |
| 96748 | 2476630 | APO-HYDROMORPHONE CR (hydromorphone hydrochloride 6 mg prolonged-release oral capsule) APOTEX INC | Dormant 2020.01.05 |
| 96749 | 2476649 | APO-HYDROMORPHONE CR (hydromorphone hydrochloride 9 mg prolonged-release oral capsule) APOTEX INC | Dormant 2010.12.12 |

## **Blacklist (on GitHub)**

The following changes have been made to the Blacklist for the OCT Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Blacklist
* ADD to Blacklist
* REMOVE from Blacklist

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 424a14b325fdd30528ddac276375d635 | adalimumab 20 mg per 0.4 mL solution for injection | 99460 | 02505258 | HYRIMOZ (adalimumab 20 mg per 0.4 mL solution for injection) SANDOZ CANADA INCORPORATED | ADD |
| 06668e24bcca98b294eeeffeec14a4af | adalimumab 40 mg per 0.8 mL solution for injection | 98214 | 02492156 | HYRIMOZ (adalimumab 40 mg per 0.8 mL solution for injection) SANDOZ CANADA INCORPORATED | ADD |
| 06668e24bcca98b294eeeffeec14a4af | adalimumab 40 mg per 0.8 mL solution for injection | 98215 | 02492164 | HYRIMOZ (adalimumab 40 mg per 0.8 mL solution for injection) SANDOZ CANADA INCORPORATED | ADD |
| 512894b9cf32cf3e45c6ad0f786aaf8a | melphalan (melphalan hydrochloride) 50 mg per vial NA | 97057 | 02480026 | TARO-MELPHALAN (melphalan (melphalan hydrochloride) 50 mg per vial NA) TARO PHARMACEUTICALS INC | ADD |
| f0c2301ff312b994626df82f32fcb4d9 | ozanimod (ozanimod hydrochloride) 0.23 mg and ozanimod (ozanimod hydrochloride) 0.46 mg oral capsule | 99536 | 02506009 | ZEPOSIA (ozanimod (ozanimod hydrochloride) 0.23 mg and ozanimod (ozanimod hydrochloride) 0.46 mg oral capsule) CELGENE INC | ADD |
| 9003541 | bismuth subsalicylate 35 mg per mL oral suspension | 96658 | 02475855 | EXTRA STRENGTH BISMUTH (bismuth subsalicylate 35.2 mg per mL oral suspension) JUNO OTC INC | REMOVE |
| 065775450e6c26847adad8849ae31770 | isoproterenol hydrochloride 0.2 mg per 1 mL solution for injection vial | 99218 | 02502615 | ISOPROTERENOL HYDROCHLORIDE INJECTION USP (isoproterenol hydrochloride 0.2 mg per 1mL solution for injection vial) MARCAN PHARMACEUTICALS INC | REMOVE |
| bfc94ece4fe302a17533c5d0175431ad | galcanezumab 100 mg per 1 mL solution for injection syringe | 99448 | 02505134 | EMGALITY (galcanezumab 100 mg per 1 mL solution for injection syringe) ELI LILLY CANADA INC | REMOVE |
| 24147720769b121b2fff60e1ca373aba | benralizumab 30 mg per 1 mL solution for injection pen | 98601 | 02496135 | FASENRA PEN (benralizumab 30 mg per 1mL solution for injection pen) ASTRAZENECA CANADA INC | REMOVE |
| 9013502 | filgrastim (pegfilgrastim) 6 mg per 0.6 mL solution for injection syringe | 99556 | 2506238 | NYVEPRIA (filgrastim (pegfilgrastim) 6 mg per 0.6 mL solution for injection syringe) PFIZER CANADA ULC | REMOVE |
| 038c93ebb9012538b29ebe4463290b60 | lanadelumab 300 mg per 2 mL solution for injection syringe | 99498 | 2505614 | TAKHZYRO (lanadelumab 300 mg per 2 mL solution for injection syringe) SHIRE PHARMA CANADA ULC | REMOVE |
| 424fa99755fc23a521f850030d52a845 | arsenic trioxide 12 mg per 6 mL solution for injection vial | 97091 | 2480387 | TRISENOX (arsenic trioxide 12 mg per 6 mL solution for injection vial) TEVA CANADA LIMITED | REMOVE |
| 9012566 | amikacin (amikacin sulfate) 500 mg per 2 mL solution for injection vial | 99595 | 2506599 | VPI-AMIKACIN (amikacin (amikacin sulfate) 500 mg per 2 mL solution for injection vial) VPI PHARMACEUTICALS INC | REMOVE |